New Treatment for CLL in USA
Patients living in the USA who have chronic lymphocytic leukaemia (CLL) now have a new treatment option with the approval of ibrutinib (Imbruvica). The Food and Drug Administration approved the use of ibrutinib in patients
with CLL who have received at least one previous therapy. Results from a phase Ib/II trial in which 48 patients with relapsed or refractory CLL received ibrutinib showed that 58% of them achieved an overall response rate that ranged from 5.6 months to 24.2 months. Ibrutinib was approved in November 2013 for the treatment of mantle cell lymphoma in patients who had received at least one prior treatment. For more information, click here.